Jie Xu

Dr. Jie Xu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Open access
LSLi Shi
Li Shi
JXJie Xu
Jie Xu
WXWenwei Xiao
Wenwei Xiao
YWYing Wang
Ying Wang
Yuefei JinYuefei Jin
Yuefei Jin
YWYadong Wang
Yadong Wang
It is unclear if there is the influence of asthma on contracting COVID-19, or having worse outcomes from COVID-19 disease. To explore the prevalence of asthma in COVID-19 patients and the relationship between asthma and COVID-19 patients with poor outcomes. The pooled prevalence of asthma in COVID-19 patients and corresponding 95% confidence interval (CI) were estimated. The pooled effect size (ES) was used to evaluate the association between asthma and COVID-19 patients with poor outcomes. The pooled prevalence of asthma in COVID-19 patients worldwide was 8.3% (95% CI 7.6-9.0%) based on 116 articles (119 studies) with 403,392 cases. The pooled ES based on unadjusted effect estimates showed that asthma was not associated with the reduced risk of poor outcomes in COVID-19 patients (ES 0.91, 95% CI 0.78-1.06). Similarly, the pooled ES based on unadjusted effect estimates revealed that asthma was not associated with the reduced risk of mortality in COVID19 patients (ES 0.88, 95% CI 0.73-1.05). However, the pooled ES based on adjusted effect estimates indicated that asthma was significantly associated with the reduced risk of mortality in COVID-19 patients (ES 0.80, 95% CI 0.74-0.86). The pooled prevalence of asthma in COVID-19 patients was similar to that in the general population, and asthma might be an independent protective factor for the death of COVID-19 patients, which suggests that we should pay high attention to COVID-19 patients with asthma and take locally tailored interventions and treatment. Further well-designed studies with large sample sizes are required to verify our findings.

30 March 2022 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
FXFei Xu
Fei Xu
CLChen Liu
Chen Liu
YDYongli Dong
Yongli Dong
WWWenyan Wu
Wenyan Wu
JXJie Xu
Jie Xu
JZJinping Zhang
Jinping Zhang
The Casitas B-lineage lymphoma (Cbl) family proteins are E3 ubiquitin ligases implicated in the regulation of various immune cells. However, their function in dendritic cells (DCs) remains unclear. To investigate the role of Cbl family members in DCs, we created dendritic cell double-deficient Casitas B lymphoma-b (Cbl-b) and Casitas B lineage lymphoma (c-Cbl) mice by crossing Cbl-b−/− mice with c-Cblflox/flox CD11c-Cre+ mice. We found that specific deletion of Cbl-b and c-Cbl in CD11c+ cells, predominantly in DCs, led to liver fibrosis, cirrhosis, and accumulation of systemic conventional Type I DCs (cDC1s) due to enhanced cell proliferation and decreased cell apoptosis. In addition to a change in DC number, double knockout (dKO) cDC1s exhibited a partially activated status as indicated by high basal expression levels of certain cytokines and possessed an enhanced capacity to prime T cells. After adoptive transfer, dKO cDC1s could drive liver fibrosis too. In further experiments, we demonstrated that Cbl-b and c-Cbl could target signal transducer and activator of transcription 5 (STAT5), a transcriptional repressor for the pro-apoptotic protein Bim, to promote ubiquitination-mediated degradation and cell apoptosis in cDC1s. Further extensive experiments revealed that Cbl-b mediated K27-linked ubiquitination of lysine 164 of STAT5a while c-Cbl induced K29-linked ubiquitination of lysine 696 of STAT5a and K27-linked ubiquitination of lysine 140 and 694 of STAT5b. Thus, our findings indicate a functional redundancy of Cbl-b and c-Cbl in cDC homeostasis and maturation.

13 November 2019 in Disease Markers
Verified
Journal Article
Open access
PDF file
CZChuanmeng Zhang
Chuanmeng Zhang
JWJiayuan Wu
Jiayuan Wu
JXJuan Xu
Juan Xu
JXJie Xu
Jie Xu
JXJianchun Xian
Jianchun Xian
JYJun Ye
Jun Ye
Background and Aim. Aspartate aminotransferase-to-platelet ratio index (APRI) is widely used in the assessment of fibrosis and cirrhosis, especially in patients with chronic hepatitis. However, the prognostic value of APRI in patients with chronic hepatitis with regard to the prediction of hepatocellular carcinoma (HCC) occurrence remains controversial. The objective of this meta-analysis is to investigate the association between APRI and HCC risk on the basis of cohort studies. Methods. We systematically reviewed PubMed, EMBASE, Web of Science, and Chinese National Knowledge Infrastructure databases for relevant cohort studies up to May 1, 2019. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for total and subgroup analyses were calculated with Stata 12.0 software for the assessment of the relationship between APRI and HCC risk. Results. A total of 13 studies, involving 8897 patients, were included in the meta-analysis, of which 11 explored the association between pretreatment APRI and HCC risk and four reported the relationship between posttreatment APRI and HCC risk. Pooled results showed that an elevated level of pretreatment APRI was associated with increased HCC risk (HR=2.56, 95% CI: 1.78–3.68). When stratified by hepatitis type, high pretreatment APRI predicted HCC development in patients with chronic hepatitis B (CHB) and C (CHC) but not in alcoholic liver cirrhosis (ALC). In the subgroup analyses of study region, cut-off value, sample size, and analysis method, the relationship between high pretreatment APRI and increased HCC risk was significant. Meanwhile, patients with a high level of posttreatment APRI suffered from high HCC risk (HR=3.69, 95% CI: 2.52–5.42). Conclusion: Results revealed a significant association between elevated APRI and HCC development in patients with chronic hepatitis, suggesting that APRI might serve as a valuable predictor for HCC risk in patients with chronic hepatitis.

28 January 2022 in Disease Markers
Verified
Journal Article
Open access
CZChuanmeng Zhang
Chuanmeng Zhang
CZChenglin Zhou
Chenglin Zhou
JXJie Xu
Jie Xu
SXShanshan Xue
Shanshan Xue
Background and Aim. Sphingosine kinase 1 (SPHK1) is a key enzyme of sphingolipid metabolism which is involved in the pathogenesis and progression of human cancer. It has been demonstrated to be upregulated in various types of human malignancies. However, the prognostic value of SPHK1 remains unclear. Therefore, we performed this meta-analysis to assess its predictive value in the prognosis of cancer patients. Methods. PubMed, Web of Science, Embase, CNKI, and Wanfang databases were thoroughly searched for eligible studies, in which the relationship between SPHK1 expression and cancer prognosis was evaluated. Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled to estimate the impact of SPHK1 expression on cancer patients’ survival. Odds ratios (ORs) and 95% CIs were combined to assess the association between SPHK1 expression and clinicopathological characteristics of cancer patients. The certainty of evidence was evaluated by Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) criteria. Results. Thirty studies comprising 32 cohorts with 5965 patients were included in this meta-analysis. The outcomes indicated that elevated SPHK1 expression was associated with worse overall survival (OS) ( HR = 1.71 , 95% CI: 1.45-2.01, P < 0.001 ) and disease-free survival (DFS) ( HR = 1.34 , 95% CI: 1.13-1.59, P = 0.001 ). What is more, SPHK1 overexpression was significantly correlated with certain phenotypes of tumor aggressiveness, such as clinical stage ( OR = 2.07 , 95% CI: 1.39-3.09, P < 0.001 ), tumor invasion ( OR = 2.16 , 95% CI: 1.47-3.18, P < 0.001 ), lymph node metastasis ( OR = 2.04 , 95% CI: 1.71-2.44, P < 0.001 ), and distant metastasis ( OR = 3.16 , 95% CI: 2.44-4.09, P < 0.001 ). The quality of the evidence for both OS and DFS was low. Conclusions. Increased SPHK1 expression is related to poor prognosis in human cancers and may serve as a promising prognostic marker and therapeutic target for malignant patients. However, conclusions need to be treated with caution because of lack of high quality of evidence.

28 November 2021 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
YCYu-Min Cao
Yu-Min Cao
XFXi-Min Fan
Xi-Min Fan
JXJie Xu
Jie Xu
JLJie Liu
Jie Liu
QFQi-Yuan Fan
Qi-Yuan Fan

20 July 2021 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Open access
PDF file
KLKirill A. Lyapichev
Kirill A. Lyapichev
SLSanam Loghavi
Sanam Loghavi
Siba El HusseinSiba El Hussein
Siba El Hussein
JAJAUDAH AL-MAGHRABI
JAUDAH AL-MAGHRABI
JXJie Xu
Jie Xu
Joseph KhouryJoseph Khoury
Joseph Khoury
Context - The main focus of education in most pathology residency and subspecialty pathology fellowships is the light microscopic examination of pathology specimens. Classes with multiheaded scopes are the most popular among pathology trainees. Until recently, it was difficult to us to imagine that this educational approach could change. In the beginning of March 2020 our country faced a serious challenge, which all of us now known as coronavirus disease 2019 (COVID-19) pandemic. The rules of social distancing and work from home were applied. These types of restrictions were implemented in almost all parts of our life including work and pathology education. Objective - To share our experience in the Department of Hematopathology at The University of Texas MD Anderson Cancer Center during COVID-19 pandemic. We describe our experience in modifying our approaches to education. We show how we overcame many obstacles to learning by building one of the largest virtual hematopathology educational platforms via Cisco WebEx and using social media, in particular Twitter. These tools facilitated the learning of hematopathology by medical students, pathology trainees, and practicing pathologists from all over the world. Data Sources - During the three months of the pandemic (April, May and June 2020), we evaluated the visitors' attendance to MD Anderson Cancer Center Hematopathology Virtual Educational Platform using data collected by Cisco WebEx website. For examination of the impact of the hematopathology community on Twitter on medical education the analytic metrics obtained from Symplur LLC (www.symplur.com, 04/27/2020) were used via its Symplur Signals program. Conclusions - Our experience using the MD Anderson Hematopathology Virtual Platform showed that there is substantial, global interest and desire for virtual hematopathology education, especially during the pandemic time.